VERA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Vera Therapeutics Inc (VERA) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the company has positive catalysts such as upcoming drug launches and favorable analyst ratings, the technical indicators, insider selling trends, and lack of strong proprietary trading signals suggest that waiting for a better entry point would be prudent. The stock's post-market price of $39.07 is near its support level, but the lack of upward momentum and potential short-term downside risk make it less appealing for immediate investment.
The MACD is negative and contracting (-0.254), indicating bearish momentum. RSI is neutral at 24.819, and moving averages are converging, showing no clear trend. The stock is trading near its support level (S1: 38.616), with resistance at R1: 43.353. The technical indicators suggest a lack of strong upward momentum.
Analysts have raised price targets significantly, with H.C. Wainwright setting a target of $110 due to priority review for atacicept.
The upcoming launch of atacicept for IgA nephropathy is a major growth opportunity.
Appointment of Christopher Hite to the board brings significant biopharma expertise.
Insiders are selling shares, with a 158.76% increase in selling activity over the last month.
The stock has an 80% chance of declining 11.5% in the next week and 6.33% in the next month, based on historical patterns.
The financials show no revenue growth and a net income loss of $91.1M in Q4 2025, despite YoY improvement.
In Q4 2025, the company reported no revenue growth (0% YoY) and a net income loss of -$91.1M, which improved by 109.78% YoY. EPS also improved to -1.39, up 93.06% YoY, but the company remains unprofitable.
Analysts are bullish, with multiple firms raising price targets (e.g., H.C. Wainwright to $110, Goldman Sachs to $95). The positive sentiment is driven by the priority review of atacicept and higher pricing potential for the drug class. However, JPMorgan slightly reduced its target to $96.
